KL co-mutation characterized 6.5% (16/248) of the NSCLC tumors included in our study, KC status 8.5% (21/248), KRAS mutant and LKB1 intact status 8.46% (21/248), KP status 5.6% (14/248), L status 2.4%, K status 1.6% (4/248), and finally, the triple-mutated KPL status only 0.4% of the tumors (1/248) [Supplementary Tables S16 and S17]. The gene discussed is STK11; the disease is non-small cell lung carcinoma.